ArticleJapanese journal of radiology2026
Hemostatic single-fraction 8 Gy radiotherapy for tumor bleeding: a single-centre retrospective study.
Article in Japanese journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe efficacy of single-fraction 8 Gy radiotherapy (RT) for achieving hemostasis remains unclear. In this study, we assessed (1) hemostatic efficacy, (2) rebleeding, and (3) factors related to hemostatic efficacy and rebleeding associated with single-fraction 8 Gy RT. MATERIALS AND
methodsPatients with tumor bleeding who received single-fraction 8 Gy RT between January 2020 and December 2024 were retrospectively examined. Factors associated with hemostasis and rebleeding (recurrence of bleeding signs/symptoms, need for red blood cell [RBC] transfusion or salvage treatment after confirmation of hemostasis or decreasing hemoglobin levels) were assessed.
resultsA total of 90 lesions in 82 patients were examined. The median follow-up time after the administration of RT treatment was 80 days (interquartile range [IQR], 35-206 days; range, 7-776 days). The overall hemostatic ratio of lesions within 30 days (= 30-day hemostatic response rate) was 68.9%. In an exploratory analysis, gastroduodenal (gastrointestinal [GI]-gastroduodenal) bleeding showed a higher 30-day hemostatic response than GI-non-gastroduodenal and non-GI sites (80.4% vs. 56.8%; odds ratio, 3.08; 95% confidence interval [CI], 1.12-9.09; p = 0.02). Additionally, among evaluable patients with or without rebleeding (n = 52), the median time to rebleeding after hemostasis was 102 days (95% CI, 69-196 days). The cumulative rebleeding rates at 30 and 60 days after hemostasis were 11.8% and 24.1%, respectively.
conclusionsAlthough this study includes patients with different cancer types, bleeding sites, and treatment backgrounds, single-fraction 8 Gy RT demonstrated potential hemostatic benefit for tumor bleeding in the palliative setting. Our findings should be interpreted cautiously because of the retrospective nature of this study.
Indexed as
Identifiers
42667561What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.